The chemotherapy matches anti-cancer medicine He match Ting breast cancer to relapse rate decrease 50%

American national cancer research two clinical researches of the center(NCI) indicate that the sufferer of breast cancer's matching anti-cancer medicine He match Ting(Herceptin) by chemotherapy after cutting off tumor can relapse breast cancer a rate to reduce a half.These two researches show that the sufferer of breast cancer after cut off the tumor if pure accept a chemotherapy, relapse the rate can reduce 33% or so, but knot the patient of up to standard chemotherapy by He match Ting, then can reduce 50% two mammary glands cancers to relapse a probability.American food and medicine administration(FDA) approve the He match appear on market of Ting in 1998, He match Ting from gene technique(Genentech) company product.The former research show that He match Ting can in aid of and 20% ～s 30% be categorized the HER － which results in for the gene mutation 2 proteins to too many causable of mammary glands cancer sufferer.The mammary glands tumor of this kind of type growth speed more quick, after operation relapse of the possibility also compares the mammary glands cancer of other types to get Gao.

NCI researcher from suffer from HER － to 3300 in 2000-2005 April, yearses 2 mammary glands cancer of the women carry on a two clinical trial, get above of result.

Anticipate in the United States to there are 210,000 or so women's associations being diagnose for the mammary glands cancer in 2005, among them, 30% belong to HER － 2 mammary glands cancers.Equally there is annually 40,000 mammary glands cancer in the United States the patient dies because of the cancer and have American cancer death rate 15% of the total amount be or so.